Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesHematology/OncologyAloha Care dose rounding Prior Auth Policy Update …
    Ask Trek AI about this page
    CurrentAloha CarePolicy RXMP-36

    Dose Rounding for Systemic Therapy

    Customize your policy alerts

    Sign up for Aloha Care Policy RXMP-36 alerts

    Get alerted when Policy RXMP-36 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines AlohaCare's policy to implement dose rounding for select systemic cancer therapies (injectable and oral) to reduce waste and cost, affecting providers submitting prior authorizations and administering cancer drugs under pharmacy and medical benefits.

    Policy Summary
    PayerAloha Care
    PolicyDose Rounding for Systemic Therapy
    Policy CodePolicy RXMP-36
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewSep 11, 2025
    Next Review DateJan 1, 2026
    Key ActionSubmit prior authorization through MBMNow; Optum's Cancer Guidance Program will calculate rounded doses and may auto-approve if the provider accepts the rounded dose.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ±10%rounding tolerance
    >=10%reauthorize if weight change

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    select listtargeted drugs
    MBMNowsubmission system

    Coverage Criteria — Dose Rounding

    When dose rounding is applied

    Dose rounding is applied when ALL of the following are met

    Rounding eligibility: 1) The drug is a select cancer drug included in Optum's Cancer Guidance Program or an injectable single-use preservative-free vial or an oral chemotherapy agent; 2) Rounding down (less than or equal to 10% from the prescribed per‑treatment dose) from the NCCN- or FDA-recommended per‑treatment dose results in use of fewer vials or fewer capsules/tablets per treatment; 3) The rounded dose does not reduce expected treatment efficacy; 4) The provider voluntarily accepts the rounded dose when it is offered (e.g., via MBMNow).within 10%

    If the provider accepts the rounded dose in MBMNow, the authorization may be auto-approved and include total approved billable units for the course of treatment.

    Dose rounding is not applied when rounding down will not result in using fewer vials, capsules, or tablets per treatment. The policy applies rounding only when a reduced dose (within the allowed tolerance) meaningfully decreases the number of single‑use vials or oral dosage units needed for that administration; if no reduction in vial or unit count occurs, do not round the dose.

    This guidance is informational and does not constitute medical advice. Providers must exercise independent clinical judgment and make treatment decisions in consultation with the patient; acceptance of a rounded dose is voluntary and is not required to obtain prior authorization.

    Coding and Tolerances

    Covered HCPCS/J-codes listed for dose roundingHCPCSCovered
    J0893Decitabine (sun pharma)
    J0893(also listed mapping: HCPCS Code = J9294 in source)
    J0894Decitabine (Dacogen®)
    J0894(also listed mapping: HCPCS Code = J9296 in source)
    J9025Azacitidine (Vidaza®)
    J9025(also listed mapping: HCPCS Code = J9297 in source)
    J9033Bendamustine (Treanda®)
    J9033(also listed mapping: HCPCS Code = J9299 in source)
    J9035Bevacizumab (Avastin®)
    J9035(also listed mapping: HCPCS Code = J9303 in source)
    1–10 of 44
    1/5
    inv-05: Dose rounding tolerance — within 10% of prescribed dose
    Dose rounding toleranceWithin 10% of the prescribed dose (±10%)
    When appliedApplied when rounding down (≤10%) to the nearest vial/capsule/tablet results in use of fewer vials or fewer capsules/tablets per treatment
    ScopeIncludes select cancer drugs in Optum's Cancer Guidance Program, preservative‑free single‑use injectable vials, and oral chemotherapy agents
    Clinical supportSupported by HOPA, reviewed/endorsed by NCCN and published by ASCO for rounding within 10%
    Effect on authorizationIf provider accepts rounded dose in MBMNow, the authorization may be auto‑approved and include total approved billable units for the course of treatment

    Provider Actions and Prior Authorization

    Prior Authorization

    Prior authorization processing via MBMNow — Optum CGP calculates rounding candidates

    When a prior authorization is submitted through MBMNow, Optum's Cancer Guidance Program automatically determines cases where dose rounding applies and calculates the per-treatment dosage based on the patient's height and/or weight and the NCCN-recommended dosage. If the provider accepts the rounded dose when offered in MBMNow, the request may be automatically approved and the authorization will include the total approved billable units for the course of treatment based on the rounded dose and approved cycles.

    • Automatic identification of rounding candidates and dose calculation performed by Optum CGP in MBMNow
    • Auto-approval possible if provider accepts the rounded dose; authorization will include total approved billable units for the course of treatment
    Step Therapy

    Step therapy — none specified

    This guideline specifies no step therapy requirements for dose rounding; there are no additional required prior treatment steps outlined.

    Background and Purpose

    Dose rounding is intended to reduce drug waste and associated costs while preserving clinical efficacy. The goals include reducing single‑use vial waste, minimizing unnecessary handling and exposure for health care personnel, and lowering overall treatment costs when a rounded dose (within policy tolerance) can be used without compromising efficacy. This policy aligns with referenced guidance (NCCN/HOPA/ASCO) and is implemented for select systemic cancer therapies through the Cancer Guidance Program.

    Definitions

    inv-11: Dose rounding definition — adjust to nearest vial/capsule within 10%
    DefinitionAdjust the prescribed dose to the nearest vial size or nearest capsule/tablet size within 10% of the prescribed dose
    IntentReduce vial/capsule/tablet use and waste while maintaining treatment efficacy
    Applicable formulationsPreservative‑free single‑use injectable vials and oral chemotherapy agents; select Optum Cancer Guidance Program drugs
    Limit on roundingRounding down should be less than or equal to 10% and only when it results in fewer vials or fewer capsules/tablets per treatment
    inv-12: Rounded dose acceptance — voluntary provider acceptance enabling auto-approval
    Nature of acceptanceVoluntary acceptance by the provider of the calculated rounded dose; providers are not required to accept rounding to receive prior authorization

    Revision History

    2025-09-11policy_revisionLatest

    Policy revised and updated; Review/Revision date 2025-09-11 reflecting adoption of Optum Cancer Guidance Program dose rounding and related details (effective date set 2026-01-01).

    2026-01-01effective_date

    Policy effective date set to 2026-01-01 as specified in the policy header.

    Policy Summary
    PayerAloha Care
    PolicyDose Rounding for Systemic Therapy
    Policy CodePolicy RXMP-36
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewSep 11, 2025
    Next Review DateJan 1, 2026
    Key ActionSubmit prior authorization through MBMNow; Optum's Cancer Guidance Program will calculate rounded doses and may auto-approve if the provider accepts the rounded dose.
    SourceLink
    On This Page
    Coverage Criteria — Dose RoundingCoding and TolerancesProvider Actions and Prior AuthorizationBackground and PurposeDefinitionsRevision History
    Documentation Required

    Submission and reauthorization — MBMNow submission; reauth for ≥10% weight change

    Providers must submit prior authorization requests through MBMNow; Optum's Cancer Guidance Program will calculate rounded doses. If a member's weight changes significantly (>=10%) during therapy, a new authorization must be submitted to ensure the total authorized dose is not exceeded.

    • Submit initial and follow-up prior authorizations via MBMNow
    • Reauthorization required when member weight changes >=10% during the course of therapy
    Denial Risk

    Custom review required if rounded dose is declined

    If the Optum Cancer Guidance Program offers a rounded dose in MBMNow and the provider declines the rounded dose, the prior authorization request will require custom review and a Cancer Guidance Program Nurse may contact the provider for additional information.

    • Declining the rounded dose prevents auto-approval and triggers custom review and possible outreach
    Impact on prior authorizationWhen the provider accepts the rounded dose (for submissions via MBMNow), the authorization may be auto‑approved
    Clinical judgmentClinicians must use independent medical judgment; acceptance is a clinical decision between physician and patient
    When rounding not appliedIf rounding down will not reduce vial or capsule/tablet use per treatment, dose rounding is not applied